Cognition Therapeutics (CGTX) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Neuraxis (NRXS) has outperformed Cognition Therapeutics (CGTX) over the past year, gaining 128.0% versus a loss of 55.0%. Neuraxis is the larger company by market cap ($87.0 million vs $83.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | NRXS |
|---|---|---|
| Share price | $0.8769 | $6.93 |
| Market cap | $83.39M | $87.03M |
| 1-day change | -2.04% | +2.36% |
| YTD return | -35.04% | +52.64% |
| 1-year return | -55.03% | +127.96% |
| 5-year return | -92.63% | — |
| EPS (TTM) | $-0.17 | $-0.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.05 | $9.33 |
| 52-week low | $0.55 | $2.21 |
| Distance from 52-week high | -57.22% | -25.72% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +279.75% | +58.73% |
| Average volume | 534.62K | 108.37K |
| Shares outstanding | 95.09M | 12.56M |
| Employees | 14 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed CGTX by 183.0 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
CGTX vs NRXS FAQ
Which is bigger, Cognition Therapeutics or Neuraxis?
Neuraxis (NRXS) is larger, with a market capitalization of $87.03M compared with $83.39M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or NRXS?
NRXS returned +127.96% over the past 12 months, compared with -55.03% for CGTX (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and Neuraxis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cognition Therapeutics and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Neuraxis.